Application: PARP inhibitor eligibility assessment
Specimen: Tumor tissue or blood
Content: HRD score + BRCA1/2 (including LGRs) + 60+ HRR genes
Highlights: - Low-pass WGS + SNP integration - Tumor purity requirement as low as 20% - CE-IVD and global patent coverage